Eligo Bioscience
Precision medicines for the microbiome
TL;DR
What they do: Develop in vivo gene-editing medicines that target bacterial genes in the human microbiome (Eligobiotics, GEM).
Headquarters: Paris, France
Founding team: Founded by Luciano Marraffini, Timothy Lu, David Bikard and Xavier Duportet
Recent funding: Series B announced Dec 5, 2023 (led by Sanofi Ventures); total funding reported $74.7M
Employee count: About 30
Company Overview
Problem Domain
Therapeutic modulation of the human microbiome via in vivo bacterial gene editing
Industry
Biotechnology
Funding Track Record
30000000
Series B announced Dec 5, 2023; participants included Bpifrance, Khosla Ventures and Seventure Partners.
20000000
5000000
France 2030 government grant for a topical gene-delivery platform; company reported expansion of Series B to $35M in this announcement.
Investor Signal
“Led by Sanofi Ventures in Series B; recurring participation from Khosla Ventures and Seventure Partners”